Elaine Chen is a national biotech reporter at STAT and co-writes The Readout newsletter. She covers a range of topics related to medicine and healthcare, with a focus on pharmaceuticals, public health, and the intersection of AI and healthcare. Elaine's work has been featured in prominent publications including BioRxiv, Yahoo Finance, Bloomberg News, and The New York Times.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Elaine Chen's coverage primarily focuses on healthcare, pharmaceuticals, and to a lesser extent finance. Her articles frequently cite data and press releases. Sources with access to relevant research findings or industry statistics may find success in pitching to her.
Given the prevalence of topics related to obesity, weight-loss drugs, and health research in her articles, Elaine would likely welcome insights from medical professionals specializing in these areas. Additionally, she might be interested in hearing from experts able to provide context around new developments within the pharmaceutical industry.
As Elaine does not have a specific geographic focus mentioned but covers international news across healthcare and finance sectors, she is likely open to receiving pitches from sources located anywhere globally who can offer valuable insights into these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Novo Nordisk sues Eli Lilly over GLP-1s, Medicare pricing plans, and more biotech news from The Readout
AI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The Readout
By: Elaine Chen
Those in Phase 3 study of retatrutide lost weight but didn't see significantly lower cardio risk
By: Allison DeAngelis, Elaine Chen
What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that's partnered with Novo Nordisk?
By: Elaine Chen, Matthew Herper
Regulators at the Food and Drug Administration have reiterated concerns that Replimune does not have adequate data to support an approval of its investigational skin cancer treatment, as the biotech tries for the third time to seek clearance for its highly controversial drug.
By: Matthew Herper, Elaine Chen
Panel's deliberations are key for company — and could signal the agency's broader posture
By: Allison DeAngelis, Adam Feuerstein, Elaine Chen
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?
By: Elaine Chen
Novo, along with other drugmakers, has wagered that reducing inflammation can lower people's risk of cardiovascular issues
By: Elaine Chen, Lizzy Lawrence
Some doctors are seeking early access to Lilly's retatrutide Last month, STAT reported that Eli Lilly granted a single, 79-year-old patient
Gilead wins case over its HIV medicine, Eli Lilly to expand retatrutide access, and more biotech news
